TABLE 1.
SARS‐CoV‐2 Surface Testing in Outpatient and Inpatient Cancer Units
| Location | No. Positive | |||
|---|---|---|---|---|
| Total | Patient/Public | Staff | Medical Equipment | |
| Outpatient | 130 | 0/85 | 0/22 | 0/23 |
| Hematologic malignancies | 73 | 0/44 | 0/16 | 0/13 |
| Medical oncology | 57 | 0/41 | 0/6 | 0/10 |
| Inpatient | 74 | 1/42 | 0/18 | 0/14 |
| Lymphoma/leukemia/CAR T cell | 36 | 0/18 | 0/12 | 0/6 |
| COVID‐19/PUI unit | 38 | 1/24 a | 0/6 | 0/8 |
Abbreviations: CAR, chimeric antigen receptor; COVID‐19, coronavirus disease 2019; PUI, person under investigation; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
Patient/public areas included toilets, waiting rooms, elevator banks, patient examination rooms (including designated isolation rooms for COVID‐19+ patients/PUIs), infusion chairs, clinic entrances/exits, and floors. Staff areas included pneumatic tube stations, the nursing station, the pharmacy, and computer equipment (ie, mouses and keyboards). Medical equipment included vital signs monitors, telemetry stations, intravenous poles, and linen carts.
The 1 positive result came from the floor with a room with a patient with multiple medical comorbidities on day 9 of hospitalization who was admitted with COVID‐19 pneumonia.